Xing Hui-Chun, Li Lan-Juan, Xu Kai-Jin, Shen Tian, Chen Yun-Bo, Sheng Ji-Fang, Chen Yu, Fu Su-Zhen, Chen Chun-Lei, Wang Jian-Guo, Yan Dong, Dai Fang-Wei, Zheng Shu-Sen
Department of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
J Gastroenterol Hepatol. 2006 Apr;21(4):647-56. doi: 10.1111/j.1440-1746.2006.04306.x.
Intestinal microflora play a crucial role in some severe liver diseases. The purpose of this study was to evaluate the effects of a Lactobacillus strain and a Bifidobacterium strain on ischemia-reperfusion (I/R) liver injury.
Rats were divided into six groups. Each group received either Bifidobacterium Catenulatum ZYB0401; Lactobacillus Fermentum ZYL0401; a mixture of these two bacterial strains; gentamicin; or saline by daily gavage for 7 days. On the sixth day, all rats, except those in the control group, were subjected to 20 min of liver ischemia. After 22 h of hepatic reperfusion, liver enzymes and histology, malondialdehyde (MDA), superoxide dismutase (SOD), endotoxemia, serum tumor necrosis factor-alpha (TNF-alpha), intestinal bacteria, intestinal mucosal ultrastructure, and bacterial translocation were studied.
All administered bacteria increased intestinal Bifidobacterium and Lactobacillus, decreased endotoxemia (P < 0.01), alanine aminotransferase (ALT) (P < 0.01), and markedly ameliorated liver histology and intestinal mucosal ultrastructure. Only rats treated with Bifidobacterium Catenulatum ZYB0401 and Lactobacillus Fermentum ZYL0401 showed reduced incidence of bacterial translocation to the kidney (P < 0.05), associated with decreased serum TNF-alpha and liver MDA (P < 0.05) and increased liver SOD (P < 0.05) compared to the I/R group. Gentamicin decreased almost all kinds of intestinal bacteria (P < 0.01) and decreased ALT (P < 0.01) and serum TNF-alpha, but failed to reduce both endotoxemia and the incidence of bacterial translocation and had no effects on liver MDA and SOD.
Bifidobacterium Catenulatum ZYB0401 in combination with Lactobacillus Fermentum ZYL0401 could be useful in restoring intestinal microflora and in preventing liver injury in hepatic I/R of rats.
肠道微生物群在某些严重肝脏疾病中起关键作用。本研究旨在评估一株乳酸杆菌和一株双歧杆菌对缺血再灌注(I/R)肝损伤的影响。
将大鼠分为六组。每组大鼠每日经口灌胃给予链状双歧杆菌ZYB0401、发酵乳杆菌ZYL0401、这两种菌株的混合物、庆大霉素或生理盐水,持续7天。在第6天,除对照组外,所有大鼠均经历20分钟的肝脏缺血。肝脏再灌注22小时后,研究肝酶和组织学、丙二醛(MDA)、超氧化物歧化酶(SOD)、内毒素血症、血清肿瘤坏死因子-α(TNF-α)、肠道细菌、肠黏膜超微结构及细菌易位情况。
所有给予的细菌均增加了肠道双歧杆菌和乳酸杆菌数量,降低了内毒素血症(P < 0.01)、丙氨酸转氨酶(ALT)(P < 0.01),并显著改善了肝脏组织学和肠黏膜超微结构。与I/R组相比,仅经链状双歧杆菌ZYB0401和发酵乳杆菌ZYL0401处理的大鼠肾脏细菌易位发生率降低(P < 0.05),同时血清TNF-α和肝脏MDA降低(P < 0.05),肝脏SOD升高(P < 0.05)。庆大霉素几乎减少了所有种类的肠道细菌(P < 0.01),降低了ALT(P < 0.01)和血清TNF-α,但未能降低内毒素血症和细菌易位发生率,且对肝脏MDA和SOD无影响。
链状双歧杆菌ZYB0401与发酵乳杆菌ZYL0401联合应用可能有助于恢复肠道微生物群,并预防大鼠肝脏I/R损伤。